3646 results for «687»
3646 results
Stentless PCI, DCB and BVS in complex scenarios
20 May 2026 – From EuroPCR 2026
This session explores the use of stentless percutaneous coronary interventions (PCI) employing drug-coated balloons (DCB) and bioresorbable scaffolds (BVS) in complex coronary scenarios. Through detailed case discussions, it addresses decision-making processes, technical considerations, and practical tips for successfully completing PCI without permanent stenting.
DCB - Going beyond in-stent restenosis
20 May 2026 – From EuroPCR 2026
This session examines the expanding role of drug-coated balloons (DCB) beyond in-stent restenosis, including treatment of acute coronary syndromes, calcified lesions, and bifurcations. It reviews current evidence supporting DCB-based revascularization and outlines essential procedural steps to optimize outcomes.
Reliability and application of angio-based physiology in daily work
20 May 2026 – From EuroPCR 2026
This session evaluates the reliability and clinical application of angiography-based physiological assessments in daily practice. Topics include comparisons of angiography-derived microvascular resistance and flow metrics with invasive methods, reproducibility of quantitative flow ratio (QFR), and its correlation with symptom burden and other imaging modalities.
Expect the unexpected when treating calcified lesions
20 May 2026 – From EuroPCR 2026
Addressing the unexpected challenges in treating calcified lesions, this session showcases novel combined strategies for managing distal small-vessel coronary perforations, alongside complex case studies involving perforations, dissections, and stent complications related to calcified nodules. It provides valuable insights into rescue techniques and complication management to improve...
Pivotal study on the ShortCut transcatheter aortic valve leaflet splitting device
16 May 2024
Coronary obstruction is a major concern in patients undergoing TAVI for degenerated bioprostheses (valve-in-valve [ViV]) and is associated with a 30-day mortality rate of around 50%.1 While several transcatheter techniques to lacerate bioprosthetic valve leaflets prior to TAVI placement (such as BASILICA) have been described, they are...
GLORIOUS - Efficacy of restrictive versus liberal oxygenation or Exenatide in patients undergoing coronary artery bypass grafting or aortic valve replacement – a randomised clinical trial
21 Nov 2024
Edoardo Zancanaro provides his take on the GLORIOUS trial presented by Sebastian Wiberg at AHA 2024 in Chicago.

Author